Company intelligence / Profile preview
MiHKAL GmbH
Germanymihkal.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
MiHKAL GmbH is an innovative startup engaged in research and development of next-generation medications targeting depressive diseases. The company’s team focuses on addressing the growing prevalence of mental health issues. No clinical results have been published yet, indicating preclinical status[1].
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on MiHKAL GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MiHKAL GmbH.